Rational design of complex formation between plasminogen activator inhibitor-1 and its target proteinases

Journal of Structural Biology

Volumn 118, Issue 3, 1997, Pages 236-242

  Aertgeerts, Kathleen ^a   De Ranter, Camiel J ^a   Booth, Nuala A ^b   Declerck, Paul J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; COMPLEX FORMATION; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

EID: 0030983024     PISSN: 10478477     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsbi.1997.3860     Document Type: Article

References (50)

1. Aertgeerts K., De Bondt H. L., De Ranter C. J., Declerck P. J. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nature Struct. Biol. 2:1995;891-897.
2. Aleshkov S. B., Fa M., Karolin J., Strandberg L., Johansson L. B.-Å., Wilczynska M., Tor N. Biochemical and Biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. J. Biol. Chem. 271:1996;21231-21238.
3. 1. J. Mol. Biol. 218:1991;595-606.
4. Björk I., Nordling K., Olson S. T. Immunologic evidence for insertion of the reactive-bond loop of antithrombin into the A β-sheet of the inhibitor during trapping of target proteinases. Biochemistry. 32:1993;6501-6505.
5. Bode W., Mayr I., Baumann U., Huber R., Stone S. R., Hofsteenge J. The refined 1.9 Å crystal structure of human α-thrombin: Interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 8:1989;3467-3475.
6. Bode W., Huber R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 204:1992;433-451.
7. Carrell R. W., Stein P. E., Fermi G., Wardell M. R. Biological implications of a 3 Å structure of dimeric antithrombin. Structure. 2:1994;257-270.
8. Dauber-Osguthorpe P., Roberts V. A., Osguthorpe D. J., Wolff J., Genest M., Hagler A. T. Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins. 4:1988;31-47.
9. Declerck P. J., De Mol M., Alessi M. C., Baudner S., Paques E.-P., Preissner K. T., Müller-Berghaus G., Collen D. Purification and characterization of a plasminogen activator inhibitor-1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J. Biol Chem. 263:1988;15454-15461.
10. Ehrlich H. J., Klein Gebbink R., Keijer J., Linders M., Preissner K. T., Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J. Biol. Chem. 265:1990;13029-13035.
11. Ehrlich H. J., Keijer J., Preissner K. T., Klein Gebbink R., Pannekoek H. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry. 30:1991;1021-1028.
12. Ehrlich H. J., Klein Gebbink R., Keijer J., Pannekoek H. Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin. J. Biol. Chem. 267:1992;11606-11611.
13. 1. Nature Struct. Biol. 3:1996;676-681.
14. Engh R. A., Huber R., Bode W., Schulze A. J. Divining the serpin inhibition mechanism: A suicide substrate "springe"? TIBTECH. 13:1995;503-510.
15. Fay W., Schapiro A., Shih J., Schleef R. R., Ginsburg D. Brief report: Complete deficiency of plasminogen activator inhibitor type 1 due to a frameshift mutation. N. Eng. J. Med. 327:1992;1729-1733.
16. Gan Z. R., Li Y., Chen Z., Lewis S. D., Shafer J. A. Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III. J. Biol. Chem. 269:1994;1301-1305.
17. Gettins P., Patston P. A., Schapira M. The role of conformational change in serpin structure and function. BioEssays. 15:1993;461-467.
18. Gils A., Knockaert I., Declerck P. J. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Biochemistry. 35:1996;7474-7481.
19. Ginsburg D., Zeheb R., Yang A. Y., Rafferty U. M., Andreasen P. A., Nielsen L., Danø K., Lebo R. V., Gelehrter T. D. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J. Clin. Invest. 78:1986;1673-1680.
20. 1. Biochemistry. 33:1994;8538-8547.
21. Huber R., Kukla D., Bode W., Schwager P., Bartels K., Deisenhofer J., Steigemann W. Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 Å resolution. J. Mol. Biol. 89:1974;73-101.
22. Jones T. A., Zou J.-Y., Cowan S. W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A47:1991;110-119.
23. Keijer J., Linders M., Wegman J. J., Ehrlich H. J., Mertens K., Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: The role of heparin, vitronectin, and the reactive site. Blood. 78:1991a;1254-1261.
24. Keijer J., Linders M., van Zonneveld A. J., Ehrlich H. J., de Boer J. P., Pannekoek H. The interaction of plasminogen activator inhibitor-1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: Localization of interaction sites and physiologic relevance. Blood. 78:1991b;401-409.
25. Lamba D., Bauer M., Huber R., Fischer S., Rudolph R., Kohnert U., Bode W. The 2.3 Å crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator. J. Mol. Biol. 258:1996;117-135.
26. Lawrence D. A., Berkenpas M. B., Palaniappan S., Ginsburg D. Localization of a vitronectin binding domain in plasminogen activator inhibitor-1. J. Biol. Chem. 269:1994;15223-15228.
27. Lawrence D. A., Ginsburg D., Day D. E., Berkenpas M. B., Verhamme I. M., Kvassman J.-O., Shore J. D. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J. Biol. Chem. 270:1995;25309-25312.
28. 1. J. Mol. Biol. 177:1984;531-556.
29. Madison E. L., Goldsmith E. J., Gerard R. D., Gething M. J., Sambrook J. F. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature. 339:1989;721-724.
30. Madison E. L., Goldsmith E. J., Gerard R. D., Gething M.-J. H., Sambrook J. F., Bassel-Duby R. S. Amino-acids residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor-1. Proc. Natl. Acad. Sci. USA. 87:1990;3530-3533.
31. Ming F., Karolin J., Aleshkov S., Strandberg L., Johansson L. B.-Å., Tor N. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: Conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Biochemistry. 34:1995;13833-13840.
32. Mottonen J., Strand A., Symersky J., Sweet R. M., Danley D. E., Geoghegan K. F., Gerard R. D., Goldsmith E. J. Structural basis of latency in plasminogen activator inhibitor-1. Nature. 355:1992;270-273.
33. Naski M. C., Lawrence D. A., Mosher D. F., Podor T. J., Ginsburg D. Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J. Biol. Chem. 268:1993;12367-12372.
34. Ny T., Sawdey M., Lawrence D., Millan J. L., Loskutoff D. J. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA. 83:1986;6776-6780.
35. Olson S. E., Björk I. Regulation of thrombin activity by antithrombin and heparin. Semin. Thromb. Hemostasis. 20:1994;373-409.
36. Padmanabhan J., Sane D. C. Localization of a vitronectin binding region of plasminogen activator inhibitor-1. Thromb. Haemostasis. 73:1995;829-834.
37. Pannekoek H., Veerman H., Lambers H., Diergaarde P., Verweij C., van Zonneveld A., van Mourik J. Endothelial plasminogen activator inhibitor (PAI): A new member of the serpin gene family. EMBO J. 5:1986;2539-2544.
38. Sali A., Blundell T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234:1993;779-815.
39. Schreuder H. A., de Boer B., Dijkema R., Mulders J., Theunissen H. J. M., Grootenhuis P. D. J., Hol W. G. J. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Struct. Biol. 1:1994;48-54.
40. Shore J. D., Day D. E., Francis-Chmura A. M., Verhamme I., Kvassman J., Lawrence D. A., Ginsburg D. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive centre loop insertion and its role in the inhibitory mechanism. J. Biol. Chem. 270:1995;5395-5398.
41. Spraggon G., Phillips C., Nowak U. K., Ponting C. P., Saunders D., Dobson C. M., Stuart D. I., Jones E. Y. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure. 3:1995;681-691.
42. Sprengers E. D., Kluft C. Plasminogen activator inhibitors. Blood. 69:1987;381-387.
43. Stein P. E., Leslie A. G. W., Finch J. T., Turnell W. G., McLaughlin P. J., Carrell R. W. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature. 347:1990;99-102.
44. Stein P. E., Carrell R. W. What do dysfunctional serpins tell us about molecular mobility and disease? Nature Struct. Biol. 2:1995;96-113.
45. Van Meijer M., Klein Gebbink R., Preissner K. T., Pannekoek H. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1). FEBS Lett. 352:1994;342-346.
46. Wagner O. F., de Vries C., Hohmann C., Veerman H., Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and kringle-2 domain of t-PA. J. Clin. Invest. 84:1989;647-655.
47. Wei A., Rubin H., Cooperman B. S., Christianson D. W. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nature Struct. Biol. 1:1994;251-257.
48. Wilczynska M., Fa M., Ohlsson P., Ny T. The inhibition mechanism of serpins: evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J. Biol. Chem. 270:1995;29652-29655.
49. 1. J. Mol. Biol. 213:1990;513-528.
50. Wright H. T., Scarsdale J. N. Structural basis for serpin inhibitor activity. Proteins. 22:1995;210-225.